ArticlePloS one2012
Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Pooled it
- Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis.Journal of neurology · 2014Pooled it
- Plasma urate concentrations and possible REM sleep behavior disorder.Annals of clinical and translational neurology · 2019Trial
- Serum urate at trial entry and ALS progression in EMPOWER.Amyotrophic lateral sclerosis & frontotemporal degeneration · 2017Trial
- Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.JAMA neurology · 2014Trial
- Sex- and Laterality-Specific Associations Between Serum Uric Acid-to-Creatinine Ratio and Gait Parameters in Parkinson's Disease.Brain and behavior · 2026Article
- Changes in nucleotide and nucleoside metabolism in zebrafish brain exposed to paraquat and 6-hydroxydopamine.Fish physiology and biochemistry · 2025Article
- Targeting uric acid: a promising intervention against oxidative stress and neuroinflammation in neurodegenerative diseases.Cell communication and signaling : CCS · 2025Review
- Neuroprotective Strategies and Cell-Based Biomarkers for Manganese-Induced Toxicity in Human Neuroblastoma (SH-SY5Y) Cells.Biomolecules · 2024Article
- Disorders of Endogenous and Exogenous Antioxidants in Neurological Diseases.Antioxidants (Basel, Switzerland) · 2023Review
- Redox dysregulation as a driver for DNA damage and its relationship to neurodegenerative diseases.Translational neurodegeneration · 2023Review
- Serum but not cerebrospinal fluid levels of allantoin are increased in de novo Parkinson's disease.NPJ Parkinson's disease · 2023Article
- Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson's disease.Molecular neurodegeneration · 2022Article
- Antioxidant Therapeutics in Parkinson's Disease: Current Challenges and Opportunities.Antioxidants (Basel, Switzerland) · 2021Review
- The Role of Oxidative Stress in Parkinson's Disease.Antioxidants (Basel, Switzerland) · 2020Review
- Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis.Annals of clinical and translational neurology · 2018Article
- Genetic variants related to urate and risk of Parkinson's disease.Parkinsonism & related disorders · 2018Article
- Level of uric acid and uric acid/creatinine ratios in correlation with stage of Parkinson disease.Medicine · 2018Observational
- Glut9-mediated Urate Uptake Is Responsible for Its Protective Effects on Dopaminergic Neurons in Parkinson's Disease Models.Frontiers in molecular neuroscience · 2018Article
- Recent Advances in Biomarkers for Parkinson's Disease.Frontiers in aging neuroscience · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Urate is a major antioxidant as well as the enzymatic end product of purine metabolism in humans. Higher levels correlate with a reduced risk of developing Parkinson's disease (PD) and with a slower rate of PD progression. In this study we investigated the effects of modulating intracellular urate concentration on 1-methyl-4-phenyl-pyridinium (MPP(+))-induced degeneration of dopaminergic neurons in cultures of mouse ventral mesencephalon prepared to contain low (neuron-enriched cultures) or high (neuron-glial cultures) percentage of astrocytes. Urate, added to the cultures 24 hours before and during treatment with MPP(+), attenuated the loss of dopaminergic neurons in neuron-enriched cultures and fully prevented their loss and atrophy in neuron-astrocyte cultures. Exogenous urate was found to increase intracellular urate content in cortical neuronal cultures. To assess the effect of reducing cellular urate content on MPP(+)-induced toxicity, mesencephalic neurons were prepared from mice over-expressing urate oxidase (UOx). Transgenic UOx expression decreased endogenous urate content both in neurons and astrocytes. Dopaminergic neurons expressing UOx were more susceptible to MPP(+) in mesencephalic neuron-enriched cultures and to a greater extent in mesencephalic neuron-astrocyte cultures. Our findings correlate intracellular urate content in dopaminergic neurons with their toxin resistance in a cellular model of PD and suggest a facilitative role for astrocytes in the neuroprotective effect of urate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.